Several targeting approaches are in development. BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate with B-lymphocyte progenitors that ...

为探究 BCMA 靶向疗法治疗多发性骨髓瘤（MM）的效果，研究人员总结 2024 ASH 年会成果，为患者带来希望。 在血液疾病的领域中，多发性骨髓瘤（Multiple Myeloma，MM）一直是困扰医学界的难题。这是一种恶性浆细胞病，随着病情发展，患者的正常造血功能受到抑制 ...

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial.

BCMA-directed cell therapy Carvykti (ciltacabtagene ... but the CARTITUDE-4 study could see it used earlier on in the treatment pathway. The study – which tested Carvykti in patients with ...